ARCA BIOPHARMA UPDATES SPECIAL PROTOCOL ASSESSMENT REQUEST TO FDA FOR GENCARO PHASE 3 ATRIAL FIBRILLATION CLINICAL TRIAL

Gencaro Phase 3 FDA SPA Amendment- FINAL